Is Regulus Therapeutics Inc. (RGLS)’s Fuel Running Low? The Stock Reaches Yearly Low Today

April 17, 2018 - By Margaret Downey

Regulus Therapeutics Inc. (NASDAQ:RGLS) Logo

Investors sentiment decreased to 1.16 in Q4 2017. Its down 0.19, from 1.35 in 2017Q3. It turned negative, as 7 investors sold Regulus Therapeutics Inc. shares while 12 reduced holdings. 10 funds opened positions while 12 raised stakes. 53.17 million shares or 9.64% less from 58.85 million shares in 2017Q3 were reported.
Millennium Management Ltd Liability Com invested in 0% or 424,400 shares. 2,872 are held by Morgan Stanley. Royal Bancorp Of Canada stated it has 109,607 shares or 0% of all its holdings. Broadfin Limited Liability Corp accumulated 1.51M shares. 27,319 were reported by D E Shaw Inc. Meeder Asset Management owns 8,981 shares or 0% of their US portfolio. Macquarie Gru Limited, a Australia-based fund reported 20,000 shares. Barclays Plc reported 89 shares. Brookstone Cap Mgmt holds 13,200 shares. Manufacturers Life Insur The invested in 0% or 6,057 shares. South Dakota Invest Council has 0.04% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS). Panagora Asset Mgmt invested in 79,080 shares or 0% of the stock. Laurion Mngmt L P accumulated 392,310 shares or 0% of the stock. Drw Securities Lc reported 100,000 shares. Hightower Advsr Limited has 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS).

The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) hit a new 52-week low and has $0.59 target or 9.00 % below today’s $0.65 share price. The 5 months bearish chart indicates high risk for the $67.11M company. The 1-year low was reported on Apr, 17 by If the $0.59 price target is reached, the company will be worth $6.04M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock increased 0.99% or $0.0063 during the last trading session, reaching $0.6455. About 460,225 shares traded. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 52.76% since April 17, 2017 and is downtrending. It has underperformed by 64.31% the S&P500.

Analysts await Regulus Therapeutics Inc. (NASDAQ:RGLS) to report earnings on May, 3. They expect $-0.15 EPS, up 60.53 % or $0.23 from last year’s $-0.38 per share. After $-0.14 actual EPS reported by Regulus Therapeutics Inc. for the previous quarter, Wall Street now forecasts 7.14 % negative EPS growth.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Among 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Regulus Therapeutics had 9 analyst reports since November 8, 2017 according to SRatingsIntel. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) earned “Hold” rating by FBR Capital on Tuesday, March 27. BMO Capital Markets maintained it with “Market Perform” rating and $1 target in Wednesday, November 8 report. Wedbush maintained it with “Buy” rating and $4.0 target in Wednesday, December 20 report. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) earned “Market Perform” rating by BMO Capital Markets on Thursday, March 8. The rating was maintained by Wedbush on Thursday, February 8 with “Buy”. Wedbush maintained the stock with “Buy” rating in Monday, March 12 report. Wedbush maintained it with “Buy” rating and $4.0 target in Monday, December 11 report.

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. The company has market cap of $67.11 million. The Company’s two lead product candidates, RG-012 and RGLS4326, are in clinical development. It currently has negative earnings. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: